Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Lantheus Holdings's share price for the quarter that ended in Mar. 2026 was $75.85. Lantheus Holdings's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 65 Mil. Therefore, Lantheus Holdings's market cap for the quarter that ended in Mar. 2026 was $4,936 Mil.
Lantheus Holdings's quarterly market cap
increased
from Sep. 2025 ($3,400 Mil) to Dec. 2025 ($4,298 Mil) and
increased
from Dec. 2025 ($4,298 Mil) to Mar. 2026 ($4,936 Mil).
Lantheus Holdings's annual market cap
increased
from Dec. 2023 ($4,248 Mil) to Dec. 2024 ($6,124 Mil) but then
declined
from Dec. 2024 ($6,124 Mil) to Dec. 2025 ($4,298 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Lantheus Holdings's Enterprise Value for Today is $7,219 Mil.
Lantheus Holdings (NAS:LNTH) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Lantheus Holdings Market Cap Related Terms
Lantheus Holdings Market Cap Historical Data
* Premium members only.
The historical data trend for Lantheus Holdings's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Lantheus Holdings's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lantheus Holdings Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lantheus Holdings's Market Cap distribution charts can be found below:
* The bar in red indicates where Lantheus Holdings's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Lantheus Holdings's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lantheus Holdings (LNTH) has a Market Cap of $7,092 Mil as of Jul. 02, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Lantheus Holdings and its competitors. According to the industry distribution chart, Lantheus Holdings ranks #63 out of 1023 companies in the Drug Manufacturers industry, placing it in the top 6.2%.
Is Lantheus Holdings' Market Cap too high?
Lantheus Holdings' current Market Cap is $7,092 Mil. The Drug Manufacturers industry median Market Cap is 213.88. Lantheus Holdings' value of $7,092 Mil is 3215.9% above this industry median. Based on the distribution chart, Lantheus Holdings ranks #63 out of 1023 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Lantheus Holdings has a GF Score™ of 82/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lantheus Holdings' Market Cap compare to LQDA and HIMS?
According to the Drug Manufacturers industry distribution chart, Lantheus Holdings ranks #63 out of 1023 companies for Market Cap. This places Lantheus Holdings in the top 6% of its industry — outperforming the majority of peers. The industry median Market Cap is 213.88. Lantheus Holdings' value of $7,092 Mil is 3215.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 213.88, based on 1,023 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lantheus Holdings's current Market Cap of $7,092 Mil is 3215.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Lantheus Holdings and its competitors. For the Drug Manufacturers industry, the median Market Cap is 213.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lantheus Holdings's current Market Cap is $7,092 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lantheus Holdings stock overvalued right now?
Based on GuruFocus' analysis, Lantheus Holdings (LNTH) is currently considered Modestly Overvalued. The stock's GF Value™ is $90.85, compared to a current price of $108.93 — trading 19.9% above its estimated fair value. The current Market Cap is $7,092 Mil and 3215.9% above the Drug Manufacturers industry median of 213.88. Lantheus Holdings' overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Lantheus Holdings (LNTH), the current Market Cap is $7,092 Mil as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lantheus Holdings (LNTH) Overvalued in 2026?
Based on GuruFocus' analysis, Lantheus Holdings stock appears to be overvalued.
The current stock price of $108.93 is trading 19.9% above its estimated GF Value™ of $90.85.
GuruFocus considers Lantheus Holdings to be Modestly Overvalued.
Key valuation signals for LNTH:
Market Cap: $7,092 Mil
GF Value™: $90.85 vs. price of $108.93 (19.9% above fair value)
Industry Position: 3215.9% above the Drug Manufacturers median (#63 of 1023)
No single metric tells the full story. See the LNTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
82GF Score
Get the complete analysis for LNTH
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LNTH has been successfully added to your 
